NASDAQ:OMER

Omeros (OMER) Stock Surges After FDA Approval of Yartemlea: Latest News, Analyst Forecasts, and 2026 Outlook

December 25, 2025 — Omeros Corporation is having the kind of week biotech investors daydream about: a long-awaited U.S. regulatory win, a sharp stock re-rating, and a sudden pivot from “development-stage hope” to “commercial-stage execution.”

25 December 2025

NASDAQ:OMER

Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open

Omeros Corporation is ending Christmas Eve 2025 as one of the market’s most volatile and news-driven movers after the U.S. Food and Drug Administration approved the company’s first commercial product — a moment investors have waited years to see.

24 December 2025

NASDAQ:OMER·Pharmaceutical Industry·Stock Market

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Biotech Bombshell: Omeros Stock Skyrockets on $2.1B Novo Nordisk Deal – What’s Next?

Omeros shares were trading around $4–$4.60 through early October, then exploded on Oct. 15. Data from the company’s IR site show OMER jumped from $4.10 to $10.42 by Oct 15 closeinvestor.omeros.com. Intraday on Oct 15, it even hit a high around $12.10. This roughly 150% one-day surge was driven by the Novo Nordisk deal. Trading volume was staggering: Benzinga reports ~89.2 million shares traded during the rallybenzinga.com. By mid-October 16 pre-market, OMER was around $9–10 per share – still far above levels seen just days priorts2.techbenzinga.com.

16 October 2025

Biotechnology·Mergers & Acquisitions·NASDAQ:OMER·Stock Market

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

On Oct. 15, Novo Nordisk and Omeros announced a landmark deal licensing zaltenibart, Omeros’s experimental MASP-3 inhibitor for rare blood/kidney diseasesinvestor.omeros.com. Under the agreement, Novo pays $340M upfront and can pay up to $2.1 billion in total milestones and royalties for exclusive global rightsinvestor.omeros.comreuters.com. Reuters reports that Omeros stock “more than doubled to $9.90” in early trading after the newsreuters.com, and by market close had settled near $10.10investing.com. TechStock² notes Omeros shares surged roughly 65% on the announcementts2.tech. The deal is structured as an asset purchase and license – not an outright acquisition – and is expected to close in Q4 2025, after which Novo will launch a global Phase 3 trial in PNH and possibly other complement disordersts2.techreuters.com.

15 October 2025

Mergers & Acquisitions·NASDAQ:OMER·NYSE:NVO·Stock Market

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

On Oct. 15, Novo Nordisk and Seattle-based Omeros announced a definitive asset purchase and license agreement. Under the terms, Novo gains exclusive global rights to zaltenibart for all indications. Omeros will receive $340 million up front and near-term milestones, plus up to $2.1 billion total with development and sales milestones and tiered royalties Novonordisk. Reuters reported Novo would pay “up to $2.1 billion” for the experimental drug Reuters. The deal is structured as a licensing asset purchase, not a full acquisition, and is expected to close in Q4 2025 Marketscreener Novonordisk.